Prior Authorization for Carvykti

CarePartners of Connecticut requires prior authorization for coverage of chimeric antigen receptor (CAR) T-cell immunotherapies, now including the medication Carvykti.

CarePartners of Connecticut will cover Carvykti (HCPCS C9098) for the treatment of relapsed or refractory multiple myeloma in accordance with the guidelines outlined in the National Coverage Determination for Chimeric Antigen Receptor (CAR) T-Cell Therapy issued by the Centers for Medicare and Medicaid Services.

For complete information, refer to the updated CarePartners of Connecticut Prior Authorization and Inpatient Notification List.